Preclinical CRO niche Atlantic Bone Screen specializes in high-quality preclinical evaluation for inflammation, osteoarticular and skin diseases, along with biomaterials for orthopedic and dental applications, presenting a clear opportunity to cross-sell to drug candidates, nutraceuticals, and cosmetic/food industry ingredients.

Full service platform With in vitro, in vivo, histology/histopathology, and imaging capabilities (microCT, X-Ray) and own rodent facilities, there is potential to offer end-to-end preclinical packages, reducing supplier management for customers and enabling larger project scopes.

Targeted markets Primary focus areas include bone-related pathologies and skin conditions, aligning with niches where contract research needs robust, specialized assays and imaging, suggesting upsell opportunities to biotech startups and established pharma pursuing bone and dermatology programs.

Growth adjacency Sister company Atl analyzed in bone research indicates potential collaboration or bundled offerings around bone biology, enabling joint pitches to clients seeking integrated discovery and preclinical testing ecosystems.

Geographic and size fit Located in France with a mid-sized team (11-50 employees) and global-ready capabilities, opportunities exist to target European biotech firms and international companies seeking colocated, high-quality preclinical services with flexible engagement models.